Tumour Sclerosis complex 2 (TSC2) is a 200.7 kDa tumor suppressor protein. Mutations within both the TSC1 and TSC2 genes are responsible for Tuberous sclerosis (TSC), an autosomal dominant genetic disorder associated with the development of benign tumors (hamartomas).
Many proteins have been shown to play a role in the regulation of the serine/threonine kinase known as target of rapamycin (TOR), a central component in a complex signaling pathway which controls cell proliferation and cell cycle progression. Negative regulation of TOR activity occurs following the over-expression of the TSC1 and TSC2 gene products, hamartin and tuberin. These act by suppressing the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and ribosomal protein S6 kinase (S6K), downstream targets of TOR involved in mRNA translation. Furthermore the TOR activator protein Rheb has been identified as a target of TSC1-TSC2 complexes. TSC2 is expressed in a range of tissues including skeletal muscle, heart, brain, placenta, pancreas, lung, liver, kidney, bilary epithelium, lymphocytes and fibroblasts.
Applications:
Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested.
Recommended Dilution:
Western Blot: 1ug/ml
Immunohistochemistry (Parraffin): 5ug/ml
Optimal dilutions to be determined by the researcher.
IHC Positive Control Tissue:
Human pancreas
Recommended Secondary Antibodies:
I1904-40A: IgG, H&L, X-Adsorbed (HRP) Pab Gt xRb
I1904-46Q: IgG, H&L (HRP) Pab Gt xRb
I1904-40J: IgG, Fc (HRP) Pab Gt xRb
I1904-40P: IgG, Fc, X-Adsorbed (HRP) Pab Gt xRb
Storage and Stability:
May be stored at 4 degrees C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.